Crystagen
Thymic bioregulator peptide
Thymic-immune bioregulator.
Half-life
~ hours
Mol. weight
~ 345.3 g/mol
Sequence
Glu-Asp-Pro (EDP)
Discussions
0 threads
Overview
A short bioregulator peptide studied for regulating gene expression in thymic tissue, with proposed support for thymus function and T-cell maturation. It belongs to the same conceptual family as thymalin/thymulin and thymosin alpha-1 but uses the ultra-short-peptide bioregulator approach to target the thymus.
Mechanism of action
Crystagen is a bioregulator peptide studied for regulating gene expression in thymic tissue. The thymus is where T cells mature, and it involutes (shrinks) with age — a central driver of immunosenescence. Crystagen applies the Khavinson bioregulator framework to that thymic target, conceptually aiming to support the thymic environment that nurtures T-cell maturation, the same biological target as thymulin and thymosin alpha-1 via a different (ultra-short peptide) approach.
Researched benefits
- Studied for thymic support
- Targets the organ of T-cell maturation
- Short bioregulator format
Considerations
- Thymic involution is hard to reverse in adults
- Evidence concentrated in one tradition
- Human data limited
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Crystagen in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Crystagen:
View Crystagen index on PubMed (NCBI)